Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | MC3R | P41968 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 3/20 | 0.35 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.35 |
| ▸ | NNMT | P40261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3625940 | 0.79 | HPGDS (0.44) | HPGDSPARP1JAK3MAP4K4CHEK2 | |
| SCHEMBL27961422 | 0.79 | MAP4K4 (0.45) | HPGDSMAP4K4CHEK2 | |
| SCHEMBL10328694 | 0.77 | HCAR2 (0.41) | AGBL2APLNR | |
| SCHEMBL12970650 | 0.77 | NNMT (0.41) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL24143680 | 0.75 | IDO1 (0.30) | — | |
| SCHEMBL1855352 | 0.75 | KDM4E (0.40) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL217899 | 0.75 | AGBL2 (0.37) | SMN1; SMN2AGBL2APLNRALDH1A1MAOB | |
| SCHEMBL5047396 | 0.75 | APLNR (0.48) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL3172153 | 0.75 | SIRT6 (0.45) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL4852706 | 0.75 | APLNR (0.36) | SIRT6SMN1; SMN2AGBL2APLNRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240308979-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| US-11505541-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2022-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308979-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | ADORA3 2839/4885TSHR 1987/4885MC4R 1784/4885 |
| US-11505541-B2 | Protein kinase C inhibitors and methods of their use | PRKCA, PRKCB, PRKCH | ADORA3 2839/4885TSHR 1987/4885MC4R 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.